查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857950

神经科学市场按产品类型、技术、应用和最终用户划分 - 全球预测 2025-2032

Neuroscience Market by Product Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，神经科学市场规模将达到 341.5 亿美元，复合年增长率为 10.72%。

主要市场统计数据
基准年 2024 151.1亿美元
预计年份：2025年 167.7亿美元
预测年份：2032年 341.5亿美元
复合年增长率 (%) 10.72%

本文简要概述了当前神经科学领域，重点关注技术创新、相关人员的整合以及影响临床应用的关键策略曲折点。

神经科学生态系统处于快速技术创新和临床范式转变的交汇点，促使学术界、产业界和医疗服务领域的领导者重新评估其优先事项和投资主题。影像解析度、讯号处理和演算法解读的进步使得诊断更加精准，治疗性介入更加精细，而工程师、临床医生和资料科学家之间日益增长的跨学科合作则加速了转化医学的进展。同时，医疗系统正面临着不断变化的报销框架和日益增长的以金额为准结果预期，这些预期强调证明临床效用和成本效益。

对推动神经科学研究和临床实践模式转移的技术、监管和商业性力量的融合进行了详细的综合分析。

技术成熟、监管演变和相关人员预期变化这三大相互关联的因素正在推动神经科学领域发生深刻的变革，重塑竞争动态和临床实践。在技​​术层面，高解析度磁振造影技术和先进脑电图平台等技术的进步提高了诊断的清晰度，并催生了新的生物标记。同时，从高阶分析流程到视觉化套件，软体方面的改进正在将原始数据转化为可操作的洞见，加速从发现到临床决策的进程。

对2025年关税调整将如何重塑神经科学技术供应商的供应链策略、采购选择和营运韧性进行全面分析

2025 年的关税和贸易调整为支持神经科学技术的供应链带来了多重复杂性，对采购、製造和服务交付等各个环节都产生了累积影响。进口零件和成品关税的提高促使许多供应商重新评估其供应商布局，并考虑地域多元化策略，以保护其营运免受贸易波动的影响。事实上，采购团队正面临更高的到岸成本和更长的前置作业时间，这促使他们在库存管理和合约条款方面做出策略性调整，以确保为临床客户和研究合作伙伴提供持续的服务。

一个多维度细分框架，将产品层级、技术模式、临床应用和购买者类型连结起来，从而提供量身定制的商业化策略。

细分市场分析揭示了每种产品、技术、应用和最终用户类别都需要独特的策略和专门的服务。依产品类型划分，市场分为设备、服务、软体。设备包括影像、监测和治疗设备。影像设备包括电脑断层扫描 (CT)、脑电图 (EEG) 和磁振造影 (MRI) 等影像方式，需要差异化的开发蓝图和临床检验路径。监测设备分为侵入性监测和非侵入性监测，每种监测方式都有不同的监管要求和临床部署考量。治疗设备包括神经调控和復健设备，这些设备需要强有力的持续疗效证据和明确的患者选择标准。服务进一步细分为咨询服务和维护服务，体现了临床整合咨询能力和售后支援的重要性。软体包括分析和视觉化软体，互通性、监管分类和使用者体验是关键的采纳因素。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 采用人工智慧主导的多模态神经影像分析进行个人化治疗计划
  • 用于治疗癫痫的即时远端检测闭合迴路神经调控植入的商业化
  • 开发基于 CRISPR 的基因编辑疗法，靶向治疗阿兹海默症中的Tau蛋白病理
  • 将神经形态运算架构整合到边缘设备中以实现即时认知处理
  • 神经发炎PET示踪剂的进展加速了多发性硬化症治疗药物的开发平臺。
  • 扩大监管管道，允许使用迷幻剂辅助性治疗通讯协定难治性忧郁症

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 按产品类型分類的神经科学市场

  • 装置
    • 影像设备
      • 电脑断层扫描设备
      • 脑波设备
      • 磁振造影设备
    • 监测设备
      • 侵入式监测设备
      • 非侵入式监测设备
    • 治疗设备
      • 神经调控装置
      • 復健设备
  • 服务
    • 咨询服务
    • 维护服务
  • 软体
    • 分析软体
    • 视觉化软体

第九章 神经科学市场（依技术划分）

  • 电脑断层扫描
  • 脑电图（EEG）
  • 功能性近红外线光谱
  • 磁振造影
  • 脑磁图

第十章 神经科学市场依应用领域划分

  • 诊断
    • 心血管疾病
    • 神经系统疾病
    • 肿瘤影像
  • 监测
  • 研究
  • 治疗
    • 神经调控
    • 復健治疗

第十一章 以最终用户分類的神经科学市场

  • 诊所
  • 医院
  • 製药公司
  • 研究所

第十二章 各地区的神经科学市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 神经科学市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国神经科学市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Roche Holding AG
    • Biogen Inc.
    • Novartis AG
    • Pfizer Inc.
    • Johnson & Johnson
    • AbbVie Inc.
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd
    • Merck & Co., Inc.
    • Sanofi SA
Product Code: MRR-C002B1C9955F

The Neuroscience Market is projected to grow by USD 34.15 billion at a CAGR of 10.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 15.11 billion
Estimated Year [2025] USD 16.77 billion
Forecast Year [2032] USD 34.15 billion
CAGR (%) 10.72%

A concise overview of the current neuroscience landscape capturing technological innovation, stakeholder convergence, and the strategic inflection points shaping clinical adoption

The neuroscience ecosystem stands at the intersection of rapid technological innovation and shifting clinical paradigms, prompting leaders across industry, academia, and healthcare delivery to reassess priorities and investment theses. Advances in imaging resolution, signal processing, and algorithmic interpretation are enabling more precise diagnostics and refined therapeutic interventions, while growing interdisciplinary collaboration between engineers, clinicians, and data scientists accelerates translational progress. Concurrently, health systems are contending with evolving reimbursement frameworks and heightened expectations for value-based outcomes, which places a premium on demonstrable clinical utility and cost-effectiveness.

Throughout this report, we emphasize the convergence of device innovation, software sophistication, and service models that together reshape how neurological conditions are detected, monitored, and treated. The introductory analysis synthesizes key drivers such as regulatory pathways that incentivize safety and performance, advances in analytics that unlock latent clinical signals, and operational demands that require scalable maintenance and consultancy support. By clarifying these forces, readers will gain a cohesive understanding of the current landscape and the strategic inflection points that will determine competitive advantage in the near to medium term.

An in-depth synthesis of converging technological, regulatory, and commercial forces that are driving paradigm shifts across neuroscience research and clinical practice

Significant transformative shifts are redefining competitive dynamics and clinical practice within neuroscience, driven by three interrelated currents: technological maturation, regulatory evolution, and shifting stakeholder expectations. On the technology front, enhancements in modalities such as high-resolution magnetic resonance techniques and advanced electroencephalography platforms are expanding diagnostic clarity and enabling novel biomarkers. Parallel improvements in software, from advanced analysis pipelines to visualization suites, are converting raw data into actionable insights, thereby accelerating the path from discovery to clinical decision-making.

Regulatory frameworks are evolving to accommodate software as a medical device and hybrid hardware-software systems, which incentivizes rigorous validation and post-market surveillance while creating clearer pathways for safer deployment. Simultaneously, purchasers and care providers are prioritizing real-world evidence and demonstrable outcomes, driving vendors to integrate services such as consultancy and maintenance into their value propositions. As a result, business models are shifting from product-centric sales to outcome-oriented solutions, with bundled offerings that combine devices, analysis software, and ongoing support gaining traction. These shifts are spurring new partnerships across device manufacturers, clinical research organizations, and analytics firms, ultimately accelerating adoption in clinical and research settings.

A comprehensive analysis of how 2025 tariff adjustments have reshaped supply chain strategies, sourcing choices, and operational resilience across neuroscience technology providers

The imposition of tariffs and trade adjustments in 2025 introduced a layer of complexity for supply chains that underpin neuroscience technologies, with cumulative impacts felt across sourcing, manufacturing, and service delivery. Increased duties on imported components and finished goods have led many suppliers to reassess supplier footprints and to consider regional diversification strategies to insulate operations from trade volatility. In practice, procurement teams face higher landed costs and longer lead times, prompting strategic shifts in inventory management and contractual terms to preserve continuity for clinical customers and research partners.

In response, several manufacturers have accelerated nearshoring and re-shoring initiatives, moving certain assembly and calibration activities closer to primary end markets to mitigate tariff exposure and reduce transit-related disruption. These changes have required capital investment and operational retooling, as well as renewed focus on supplier qualification and local regulatory compliance. Moreover, service providers that rely on cross-border technician mobility and spare-part exchanges have had to adapt service models, investing in local technician training and regional parts depots to maintain responsiveness. Taken together, these adaptations highlight the need for flexible supply chain strategies that balance cost, compliance, and uptime in the face of evolving trade policy.

A multidimensional segmentation framework linking product hierarchies, modality technologies, clinical applications, and purchaser types to inform tailored commercialization strategies

Segmentation analysis illuminates how distinct product, technology, application, and end-user categories demand tailored strategies and specialized offerings. Based on Product Type, the market can be parsed into Devices, Services, and Software, with Devices encompassing Imaging Devices, Monitoring Devices, and Therapeutic Devices. Within Imaging Devices, modalities such as Computed Tomography Devices, Electroencephalography Devices, and Magnetic Resonance Imaging Devices require differentiated development roadmaps and clinical validation pathways. Monitoring Devices break down into Invasive Monitoring Devices and Non Invasive Monitoring Devices, each presenting divergent regulatory requirements and clinical deployment considerations. Therapeutic Devices include Neuromodulation Devices and Rehabilitation Devices, which necessitate strong evidence of sustained outcomes and clear patient selection criteria. Services further subdivide into Consultancy Services and Maintenance Services, reflecting the importance of advisory capabilities and post-sale support for clinical integration. Software comprises Analysis Software and Visualization Software, where interoperability, regulatory classification, and user experience are critical adoption levers.

Based on Technology, offerings span Computed Tomography, Electroencephalography, Functional Near Infrared Spectroscopy, Magnetic Resonance Imaging, and Magnetoencephalography, each technology bringing specific sensitivity profiles, requirements for shielding and environment control, and distinct data management needs. Based on Application, the landscape includes Diagnostics, Monitoring, Research, and Therapy, with Diagnostics further focused on cardiovascular disorders, neurological disorders, and oncology imaging, while Therapy emphasizes neuromodulation and rehabilitation therapy. Each application area imposes unique clinical utility thresholds and evidence requirements, influencing product development and commercialization strategies. Based on End User, primary purchasers include Clinics, Hospitals, Pharmaceutical Companies, and Research Institutes, and each end user type shows different procurement cycles, capital planning horizons, and expectations for integration and service levels. When considered together, these segmentation layers provide a multidimensional framework that supports nuanced go-to-market decisions, prioritization of R&D efforts, and the design of tailored commercial models aimed at accelerating adoption across diverse customer profiles.

Strategic regional perspectives on adoption dynamics, regulatory landscapes, and commercialization priorities across the Americas, Europe Middle East & Africa, and Asia Pacific

Regional dynamics exert a profound influence on strategic priorities, regulatory approaches, and the pace of clinical adoption. In the Americas, innovation hubs and established clinical research networks drive early adoption of advanced imaging and monitoring devices, while reimbursement environments and large integrated delivery networks shape procurement timetables and demand for demonstrated value. Clinical trial activity and collaborations with pharmaceutical developers also create demand for research-grade instrumentation and analytics platforms.

In Europe, the Middle East & Africa, regulatory harmonization efforts and centralized health technology assessment bodies influence the evaluation criteria for new technologies, and heterogeneous reimbursement pathways require customized market access strategies. Additionally, public healthcare systems in several countries prioritize cost-effectiveness and scalability, prompting suppliers to emphasize total cost of ownership and service reliability. The Asia-Pacific region is characterized by rapid infrastructure investment, growing clinical research capacity, and diverse adoption curves across countries. Markets in this region often present opportunities for localized manufacturing, partnerships with academic centers, and tailored training programs to support clinical adoption. Across these regions, strategic considerations include supply chain localization, alignment with regional regulatory expectations, and the development of culturally appropriate training and support materials to ensure successful deployment and sustained use.

Company-level analysis highlighting how integration of hardware, software, and services combined with evidence and interoperability drives competitive differentiation

Key company-level insights reveal a competitive landscape where differentiation is increasingly driven by integrated solutions, evidence generation, and after-sales service excellence. Leading device manufacturers are investing in higher-resolution hardware and modular platforms that support multi-modal imaging and streamlined upgrade paths, enabling long-term customer relationships and reduced lifecycle friction. At the same time, specialized software firms are gaining influence by delivering advanced analysis engines and user-centric visualization tools that reduce interpretation time and enhance diagnostic confidence.

Partnerships between hardware vendors and analytics providers are becoming more commonplace, creating bundled offerings that combine devices, analysis software, and consultancy services to accelerate clinical adoption. Service organizations that can demonstrate rapid deployment capabilities, robust maintenance networks, and regionally accredited training programs are achieving competitive advantage by minimizing downtime and supporting consistent outcomes. Firms that prioritize interoperability, data security, and compliance with evolving regulatory expectations are better positioned to secure large institutional contracts. Collectively, these company-level trends underscore the importance of cross-functional coordination between R&D, regulatory affairs, clinical affairs, and commercial teams to translate technical innovation into sustained market impact.

Actionable strategic and operational recommendations for leaders to strengthen resilience, evidence generation, and integrated commercial models that accelerate clinical adoption

Industry leaders should pursue a set of pragmatic actions to translate insights into operational advantage, beginning with strategic portfolio prioritization that aligns product development resources with high-impact clinical applications and supportive regulatory pathways. Priorities should include strengthening data interoperability, investing in robust validation studies that demonstrate real-world clinical benefit, and designing flexible commercial models that bundle devices, analytics, and services. By doing so, organizations can reduce friction at the point of care and better align with payer and provider expectations.

Operationally, firms should accelerate supply chain resilience initiatives, including diversification of component sourcing, establishment of regional service hubs, and investment in local technician training programs to maintain uptime in the face of trade or logistics disruptions. Commercial teams ought to develop tailored go-to-market approaches for distinct end-user segments, offering differentiated value propositions for clinics, hospitals, pharmaceutical companies, and research institutes. Moreover, forging strategic alliances with early adopter institutions and academic centers can produce the clinical evidence and case studies needed to scale adoption. Finally, leaders should actively monitor regulatory trends and participate in standards-setting forums to shape policy and ensure smoother market entry for integrated hardware-software solutions.

A transparent, multi-method research approach combining expert interviews, literature synthesis, and scenario analysis to validate findings and support actionable conclusions

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure rigor and relevance. Primary research included structured interviews with domain experts encompassing clinicians, regulatory specialists, procurement leaders, and R&D executives to capture on-the-ground perspectives. Secondary research comprised a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public filings to triangulate findings and verify technology-specific considerations such as modality performance and deployment requirements.

Analytical techniques applied include comparative technology assessments, value-chain mapping, and scenario analysis to evaluate the implications of policy changes and supply chain disruptions. Evidence synthesis prioritized reproducibility and transparency, with clear documentation of data sources, inclusion criteria, and assumptions used in qualitative interpretation. In addition, iterative validation workshops with subject-matter experts were conducted to test preliminary conclusions and enhance the practical applicability of recommendations. Collectively, these methods provide a robust foundation for insights that are both evidence-based and actionable within clinical, research, and commercial contexts.

A forward-looking synthesis outlining how integration of technology, validation, and resilient operations will determine competitive advantage and clinical impact in neuroscience

In conclusion, the neuroscience sector is navigating a period of accelerated transformation driven by technological advances, shifting regulatory frameworks, and evolving commercial expectations. The interplay between device innovation, sophisticated software capabilities, and enhanced service models is creating new pathways for earlier diagnosis, more precise monitoring, and more effective therapies. Supply chain adjustments and regional regulatory dynamics add complexity but also present opportunities for strategic differentiation through localized manufacturing, superior service networks, and targeted evidence generation.

Looking ahead, organizations that prioritize integrated solutions, invest in rigorous clinical validation, and cultivate resilient operational models will be best positioned to capture emerging opportunities. Cross-sector collaboration, informed by transparent data-sharing practices and interoperability standards, will accelerate adoption and improve patient outcomes. By synthesizing the insights presented across these sections, decision-makers can develop focused strategies to navigate uncertainty, align resources with clinical needs, and deliver sustainable value to patients and healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven multimodal neuroimaging analytics for personalized treatment planning
  • 5.2. Commercialization of closed-loop neuromodulation implants for epilepsy with real-time telemetry
  • 5.3. Development of CRISPR-based gene editing therapies targeting tau pathology in Alzheimer's disease
  • 5.4. Integration of neuromorphic computing architectures in edge devices for real-time cognitive processing
  • 5.5. Advancements in neuroinflammation PET tracers accelerating multiple sclerosis drug development pipelines
  • 5.6. Expansion of psychedelic-assisted therapy protocols for treatment-resistant depression under regulatory frameworks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuroscience Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Imaging Devices
      • 8.1.1.1. Computed Tomography Devices
      • 8.1.1.2. Electroencephalography Devices
      • 8.1.1.3. Magnetic Resonance Imaging Devices
    • 8.1.2. Monitoring Devices
      • 8.1.2.1. Invasive Monitoring Devices
      • 8.1.2.2. Non Invasive Monitoring Devices
    • 8.1.3. Therapeutic Devices
      • 8.1.3.1. Neuromodulation Devices
      • 8.1.3.2. Rehabilitation Devices
  • 8.2. Services
    • 8.2.1. Consultancy Services
    • 8.2.2. Maintenance Services
  • 8.3. Software
    • 8.3.1. Analysis Software
    • 8.3.2. Visualization Software

9. Neuroscience Market, by Technology

  • 9.1. Computed Tomography
  • 9.2. Electroencephalography
  • 9.3. Functional Near Infrared Spectroscopy
  • 9.4. Magnetic Resonance Imaging
  • 9.5. Magnetoencephalography

10. Neuroscience Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Cardiovascular Disorders
    • 10.1.2. Neurological Disorders
    • 10.1.3. Oncology Imaging
  • 10.2. Monitoring
  • 10.3. Research
  • 10.4. Therapy
    • 10.4.1. Neuromodulation
    • 10.4.2. Rehabilitation Therapy

11. Neuroscience Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Institutes

12. Neuroscience Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neuroscience Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuroscience Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Roche Holding AG
    • 15.3.2. Biogen Inc.
    • 15.3.3. Novartis AG
    • 15.3.4. Pfizer Inc.
    • 15.3.5. Johnson & Johnson
    • 15.3.6. AbbVie Inc.
    • 15.3.7. Eli Lilly and Company
    • 15.3.8. Teva Pharmaceutical Industries Ltd
    • 15.3.9. Merck & Co., Inc.
    • 15.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROSCIENCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROSCIENCE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS NEUROSCIENCE MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS NEUROSCIENCE MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS NEUROSCIENCE MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS NEUROSCIENCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE, MID